Latest Guidelines for Endometrial Cancer Management
The most current evidence-based management of endometrial cancer is defined by the 2025 ESGO-ESTRO-ESP guidelines, which integrate molecular classification with the 2023 FIGO staging system to guide surgical approach, adjuvant therapy decisions, and risk stratification 1.
Key Updates in 2025 Guidelines
Molecular Classification Integration
The 2025 guidelines fundamentally changed endometrial cancer management by incorporating four molecular subtypes into risk stratification 1:
- POLEmut (POLE-mutated): Best prognosis
- MMRd (Mismatch repair deficient): Intermediate prognosis
- NSMP (No specific molecular profile): Intermediate prognosis when low-grade and ER-positive
- p53abn (p53 abnormal): Worst prognosis
This molecular classification is now mandatory for optimal treatment planning and supersedes histology-based risk assessment alone 1.
Risk-Stratified Treatment Approach
Low Risk (No adjuvant therapy recommended) 1:
- Stage IA POLEmut, MMRd, or NSMP low-grade ER-positive
- Stage IB POLEmut
- Stage IC POLEmut or MMRd
- Stage II POLEmut
Intermediate Risk (Vaginal brachytherapy recommended) 1:
- Stage IB MMRd or NSMP low-grade ER-positive
- Stage IIA NSMP low-grade ER-positive
- Stage IIC MMRd with myoinvasion, without cervical stromal invasion and without substantial LVSI
High-Intermediate Risk (External beam radiotherapy recommended) 1:
- Stage IIA MMRd
- Stage IIB MMRd or NSMP low-grade ER-positive
- Stage IIC MMRd with cervical invasion or substantial LVSI
Surgical Management Updates
Sentinel Lymph Node Mapping has become the standard of care, with indications expanding from 59% to 83% of patients under the 2025 guidelines, while systematic pelvic lymphadenectomy decreased from 39% to 10% 2. The indocyanine green sentinel node procedure is now the reference technique for FIGO I and II staging regardless of histological type 3.
Ovarian Preservation can be considered in women younger than 45 years with FIGO 2023 IA1 or IA2 who have low risk by molecular classification. Bilateral salpingectomy is recommended when ovaries are preserved. Critical caveat: Ovaries should never be preserved in Lynch syndrome carriers (MLH1, MSH2, MSH6, PMS2 mutations) or BRCA mutation carriers 1.
Advanced and Metastatic Disease
For Stage III-IV optimally debulked disease, chemotherapy is superior to radiation alone. The GOG-122 trial demonstrated improved overall survival (55% vs 42%, P=0.004) with doxorubicin-cisplatin chemotherapy versus whole abdominal radiation 4.
First-line systemic therapy for advanced/recurrent disease 5, 6:
- Preferred: Carboplatin/paclitaxel (response rate 40-62%, OS 13-29 months)
- Carboplatin/paclitaxel/bevacizumab
- Carboplatin/docetaxel
Immunotherapy Revolution: For MSI-high or dMMR tumors (approximately 28% of endometrial cancers), immune checkpoint inhibitors have transformed outcomes 7. Pembrolizumab received FDA approval for MSI-high tumors across all cancer types, with 78% of responders maintaining response for at least 6 months 7. The 2025 NCCN guidelines now include three ICIs in combination with chemotherapy as primary or adjuvant therapy for advanced disease 6.
High-Risk Histologies
Serous and clear cell carcinomas require complete surgical staging including omentectomy, appendectomy, and peritoneal biopsies 8. Platinum-based adjuvant chemotherapy improves progression-free and overall survival even in early-stage disease (stage I-II) 8.
Combined Modality Therapy
For high-risk disease (stage I grade 3, stage II-III, serous/clear cell), pooled analysis of NSGO-EC-9501/EORTC-55991 and MaNGO ILIADE-III trials showed combined chemotherapy plus radiotherapy reduced relapse risk by 36% (HR 0.64, P=0.04) and improved cancer-specific survival (HR 0.55, P=0.01) compared to radiotherapy alone 4.
Recurrent Disease Management
Vaginal recurrence: External beam radiotherapy plus vaginal brachytherapy achieves 50% 5-year survival 4.
Systemic recurrence - hormonal therapy options for endometrioid histology only 5:
- Progestational agents (25% response rate)
- Tamoxifen (20% response rate in progesterone-refractory disease)
- Aromatase inhibitors
- Everolimus plus letrozole: 32% objective response rate, median OS 31 months 5
Important contraindication: Progestins are not recommended for adjuvant treatment of endometrial cancer 4.
Critical Practice Points
Avoid these common pitfalls:
- Do not perform routine lymphadenectomy in stage I disease without high-risk features—sentinel node mapping is now standard 1, 2
- Do not use radiation alone for stage III-IV optimally debulked disease—chemotherapy is superior 4
- Do not omit molecular testing—it fundamentally changes risk stratification and treatment decisions 1
- Do not preserve ovaries in Lynch syndrome or BRCA carriers 1
Quality of life considerations: PORTEC-2 demonstrated vaginal brachytherapy provides equivalent efficacy to external beam radiation in intermediate-risk disease with superior quality of life 4.
The 2025 guidelines represent a paradigm shift toward precision medicine in endometrial cancer, with molecular classification enabling more accurate risk stratification and leading to meaningful modifications in surgical and adjuvant management for approximately 10% of patients 2.